ABBVIE INC. (NYSE:ABBV) Files An 8-K Results of Operations and Financial Condition
Item 2.02.Results of Operations and Financial Condition
On January27, 2017, AbbVie Inc. issued a press release announcing
its financial results for the fourth quarter and full year ended
December31, 2016. A copy of the press release is furnished as
Exhibit99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
|
ExhibitNo. |
|
Exhibit |
|
99.1 |
Press Release dated January27, 2017 (furnished to Item |
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
ABBVIE INC. |
||
|
Date: January27, 2017 |
By: |
/s/ William J. Chase |
|
William J. Chase |
||
|
Executive Vice President, |
||
|
Chief Financial Officer |
EXHIBITINDEX
|
Exhibit No. |
|
Exhibit |
|
99.1 |
Press Release dated January27, 2017 (furnished |
About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products. ABBVIE INC. (NYSE:ABBV) Recent Trading Information
ABBVIE INC. (NYSE:ABBV) closed its last trading session down -0.11 at 61.27 with 7,765,266 shares trading hands.
